Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study
- 1 October 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 9 (10) , 1004-1010
- https://doi.org/10.2459/jcm.0b013e3282f9abe7
Abstract
We evaluated the acute and long-term results of the use of a new intracardiac microaxial pump, the Impella Recover LP 2.5, during elective high-risk percutaneous coronary interventions in a two-centre registry. Ten consecutive patients with poor left ventricular function and multivessel or left main coronary artery disease were considered at high risk of haemodynamic compromise and underwent percutaneous coronary interventions with preintervention Impella implantation. Procedural complications, 30-day and 12-month clinical outcome were recorded. Left ventricular ejection fraction was assessed by echocardiography before procedure and after at least 6 months. The Impella was implanted before percutaneous coronary interventions by femoral approach and percutaneous coronary interventions were successfully performed (by contra lateral femoral or radial approach) in all cases. After percutaneous coronary intervention, Impella was removed in all patients, and haemostasis was obtained by prolonged manual compression or by double suture device preimplantation technique. No access-site complication was observed and no patient required transfusions. One patient died after Impella removal due to acute stent thrombosis. The other patients had an uncomplicated in-hospital course and were discharged within 5 days. At 1-year follow-up, no patient died nor suffered acute myocardial infarction, whereas two patients underwent re-percutaneous coronary intervention. Left ventricular ejection fraction at follow-up increased significantly in this study population (from 31 ± 7% to 41% ± 13%, P = 0.02). Our results support the feasibility and safety of Impella-assisted percutaneous coronary intervention in high-risk patients. Prospective randomized trials are needed to test the clinical impact of such an innovative approach.Keywords
This publication has 10 references indexed in Scilit:
- A case of fatal stent thrombosis after Carbostent implantation: Is clopidogrel alone antiplatelet therapy a safe alternative to aspirin alone antiplatelet therapy?International Journal of Cardiology, 2007
- Elective versus provisional intraaortic balloon pumping in unprotected left main stentingAmerican Heart Journal, 2006
- Safety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5The American Journal of Cardiology, 2006
- High-risk percutaneous coronary intervention using the intracardiac microaxial pump ‘Impella Recover’Journal of Cardiovascular Medicine, 2006
- Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous impella recover LP 2.5 assist device during high‐risk coronary interventionCatheterization and Cardiovascular Interventions, 2005
- Miniature Intracardiac Assist Device Provides More Effective Cardiac Unloading and Circulatory Support During Severe Left Heart Failure Than Intraaortic Balloon PumpingChest, 2004
- Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplastyAmerican Heart Journal, 2003
- Left ventricular support by Catheter-Mountedaxial flow pump reduces infarct sizeJournal of the American College of Cardiology, 2003
- Counterpulsation: Historical Background, Technical Improvements, Hemodynamic and Metabolic EffectsCardiology, 1994
- Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1992